Blue marine therapy: Sea as a trove of natural anticancer drugs

Lindequist, 2016, Marine-derived pharmaceuticals - challenges and opportunities, Biomol Ther, 24, 561, 10.4062/biomolther.2016.181 Kiuru, 2014, Exploring marine resources for bioactive compounds, Planta Med, 80, 1234, 10.1055/s-0034-1383001 Cappello, 2021, From life in the sea to the clinic: the marine drugs approved and under clinical trial, Life, 11, 1390, 10.3390/life11121390 Mora, 2011, How many species are there on earth and in the ocean? Mace GM, editor, PLoS Biol, 9, e1001127, 10.1371/journal.pbio.1001127 Blunt, 2007 Ercolano, 2019, New drugs from the sea: pro-apoptotic activity of sponges and algae derived compounds, Marine Drugs, 17, 31, 10.3390/md17010031 Nuzzo, 2022, Antitumor potential of immunomodulatory natural products, Marine Drugs, 20, 386, 10.3390/md20060386 Gao, 2021, Marine antitumor peptide dolastatin 10: biological activity, structural modification and synthetic chemistry, Marine Drugs, 19, 363, 10.3390/md19070363 Dyshlovoy, 2019, Marine compounds and cancer: the first two decades of xxi century, Marine Drugs, 18, 20, 10.3390/md18010020 Nweze, 2020, Antibiotics development and the potentials of marine-derived compounds to stem the tide of multidrug-resistant pathogenic bacteria, fungi, and protozoa, Marine Drugs, 18, 145, 10.3390/md18030145 Cowan, 1997, The marine biosphere: a global resource for biotechnology, Trends Biotechnol, 15, 129, 10.1016/S0167-7799(97)01027-5 Barreca, 2020, Marine anticancer agents: an overview with a particular focus on their chemical classes, Marine Drugs, 18, 619, 10.3390/md18120619 Siegel, 2023, Cancer statistics, 2023, Cancer J Clin, 73, 17, 10.3322/caac.21763 PANOKFR2022, 2022 Chow, 2022, Clinical implications of T cell exhaustion for cancer immunotherapy, Nat Rev Clin Oncol, 19, 775, 10.1038/s41571-022-00689-z Brianna, 2023, Chemotherapy: how to reduce its adverse effects while maintaining the potency?, Med Oncol, 40, 88, 10.1007/s12032-023-01954-6 Khalifa, 2019, Marine natural products: a source of novel anticancer drugs, Marine Drugs, 17, 491, 10.3390/md17090491 Zuo, 2021, Development of marine-derived compounds for cancer therapy, Marine Drugs, 19, 342, 10.3390/md19060342 Jimenez, 2020, Enriching cancer pharmacology with drugs of marine origin, Br J Pharmacol, 177, 3, 10.1111/bph.14876 Ellison, 1968, Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults, Blood, 32, 507, 10.1182/blood.V32.4.507.507 Bryan, 1974, Cytosine arabinoside and 6-thioguanine in refractory acute lymphocytic leukemia, Cancer, 33, 539, 10.1002/1097-0142(197402)33:2<539::AID-CNCR2820330232>3.0.CO;2-E Herzig, 1983, High-dose cytosine arabinoside therapy for refractory leukemia, Blood, 62, 361, 10.1182/blood.V62.2.361.361 Keating, 1989, Fludarabine: a new agent with major activity against chronic lymphocytic leukemia, Blood, 74, 19, 10.1182/blood.V74.1.19.19 O’Brien, 1996, Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia, Ann Oncol, 7, S27, 10.1093/annonc/7.suppl_6.S27 Markham, 2020, Lurbinectedin: first approval, Drugs, 80, 1345, 10.1007/s40265-020-01374-0 Cho, 2022, Tumor-specific monomethyl auristatin E (MMAE) prodrug nanoparticles for safe and effective chemotherapy, Pharmaceutics, 14, 2131, 10.3390/pharmaceutics14102131 Buckel, 2015, Tumor Radiosensitization by monomethyl auristatin e: mechanism of action and targeted delivery, Cancer Res, 75, 1376, 10.1158/0008-5472.CAN-14-1931 Lacouture, 2022, Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin, The Oncologist, 27, e223, 10.1093/oncolo/oyac001 Viscuse, 2021, Front Oncol, 11, 621591, 10.3389/fonc.2021.621591 Wu, 2019, Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma, Dermatol Online J, 25, 10.5070/D3252042890 Wahab, 2021, Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma, Front Oncol, 11, 678634, 10.3389/fonc.2021.678634 Offidani, 2021, Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety, DDDT, 15, 2401, 10.2147/DDDT.S267404 Aschauer, 2022, Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy, Am J Ophthalmol, 242, 116, 10.1016/j.ajo.2022.06.009 Potts, 2011, Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials, CCDT, 11, 254, 10.2174/156800911794519716 Raninga, 2020, Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition, Theranostics, 10, 5259, 10.7150/thno.42705 Takahashi, 2021, A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer, Int J Clin Oncol, 26, 1977, 10.1007/s10147-021-01973-1 Pautier, 2021, A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery, ESMO Open, 6, 100209, 10.1016/j.esmoop.2021.100209 Martin-Broto, 2016, Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish group for research on sarcoma study, J Clin Oncol, 34, 2294, 10.1200/JCO.2015.65.3329 Svoboda, 2020, Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas, Haematol, 106, 1705, 10.3324/haematol.2019.238675 Hutchings, 2021, Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study, Hematol Oncol, 39, 185, 10.1002/hon.2838 Connors, 2018, Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma, N Engl J Med, 378, 331, 10.1056/NEJMoa1708984 Abramson, 2019, Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma, Blood, 134, 606, 10.1182/blood.2019001272 Kumar, 2021, Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma, JCO, 39, 2257, 10.1200/JCO.21.00108 Evens, 2018, Multicenter phase ii study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma, JCO, 36, 3015, 10.1200/JCO.2018.79.0139 LaCasce, 2018, Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma, Blood, 132, 40, 10.1182/blood-2017-11-815183 Horwitz, 2019, Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial, Lancet, 393, 229, 10.1016/S0140-6736(18)32984-2 Terui, 2021, A phase 2 study of polatuzumab vedotin+bendamustine+rituximab in relapsed/refractory diffuse large B-cell lymphoma, Cancer Sci, 112, 2845, 10.1111/cas.14937 Cheson, 2021, Diffuse large B-cell lymphoma: new targets and novel therapies, Blood Cancer J, 11, 68, 10.1038/s41408-021-00456-w Northend, 2022, Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL, Blood Adv, 6, 2920, 10.1182/bloodadvances.2021005953 Sehn, 2022, Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data, Blood Advances, 6, 533, 10.1182/bloodadvances.2021005794 Wani, 2014, Nature as a remarkable chemist: a personal story of the discovery and development of Taxol, Anti-Cancer Drugs, 25, 482, 10.1097/CAD.0000000000000063 2022 United Nations Conference, 2022 Tan, 2023, Impact of marine chemical ecology research on the discovery and development of new pharmaceuticals, Marine Drugs, 21, 174, 10.3390/md21030174